Health · Medical Research · 2 hrs ago

Sellas says leukemia immunotherapy cut death risk in Phase 3 trial

Sellas says leukemia immunotherapy cut death risk in Phase 3 trial

Sellas Life Sciences said its experimental treatment succeeded in a Phase 3 trial for some patients with acute myeloid leukemia.

The treatment, called galinpepimut-S, is described as a blood cancer immunotherapy and cancer vaccine.

It reduced the risk of death by 41% compared with standard treatment, the company said.

The trial involved patients with advanced acute myeloid leukemia, a blood cancer.

The result met the trial’s main goal, according to Sellas.

The available information does not say what the company plans to do next.

2 sources

Related

What people are saying

Adam FeuersteinSTAT senior writer and biotech columnist
It looks like I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy.
via STAT